In:
Pharmacogenomics, Future Medicine Ltd, Vol. 24, No. 5 ( 2023-04), p. 269-281
Abstract:
Aim: We examined whether ADIPOQ (rs266729 and rs1501299) and NOS3 (rs3918226 and rs1799983) SNPs or the haplotypes formed by them, affect blood pressure (BP) control in 196 patients with adherence to antihypertensive therapy grouped into controlled (BP 〈 140/90 mmHg) and uncontrolled (BP ≥140/90 mmHg) hypertension. Materials & methods: The average of the three most recent BP measurements was retrieved from the patients' electronic medical records. Adherence to antihypertensive therapy was evaluated using the Morisky–Green test. Haplotype frequencies were estimated using Haplo.stats. Multiple logistic/linear regression analyses were adjusted for the covariates ethnicity, dyslipidemia, obesity, cardiovascular disease and uric acid. Results: ADIPOQ rs266729 genotypes CG (additive model) and CG+GG (dominant model) were associated with uncontrolled hypertension and CG was associated with higher systolic BP and mean arterial pressure (p 〈 0.05). ADIPOQ haplotypes ‘GT’ and ‘GG’ were associated with uncontrolled hypertension and ‘GT’ was associated with higher diastolic BP and mean arterial pressure (p 〈 0.05). Conclusion: ADIPOQ SNPs and haplotypes affect BP control in hypertensive patients undergoing treatment.
Type of Medium:
Online Resource
ISSN:
1462-2416
,
1744-8042
DOI:
10.2217/pgs-2023-0012
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2023
SSG:
15,3
Bookmarklink